Ocrelizumab 300mg/10ml solution for infusion vials
NHS hospitals in England used £174,078,180 of indicative cost of Ocrelizumab 300mg/10ml solution for infusion vials in the 12 months to April 2026, about 0.7% of all hospital medicines spend. That is down 11.1% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Ocrelizumab 300mg/10ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Ocrelizumab 300mg/10ml solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Imperial College Healthcare Nhs Trust | £25,123,550 |
| Univ Hpl B/Ham Nhs Foundation Trust | £10,379,930 |
| Barts Health Nhs Trust | £9,465,040 |
| Sheffield Teaching Hospitals Nhs Trust | £9,254,280 |
| University Hpls North Midlands Nhs Trust | £7,726,270 |
| King's College Hpl Nhs Foundation Trust | £6,849,700 |
| University College London Foundation Tr | £6,025,820 |
| Leeds Teaching Hpls Nhs Trust | £5,225,890 |
| Salford Royal Nhs Foundation Trust | £4,593,610 |
| Cambridge Univ Hosp Nhs Foundation Trust | £4,382,850 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.